Name: Botanix Pharmaceuticals (BOT) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

BOT

Pharmaceuticals, Biotechnology & Life Sciences

Botanix Pharmaceuticals

Short interest: 0.63%; +0.01 pp 30d; as of 8 Oct 2026
Reported shorts: 17.3M
Shares on issue: 2.762B

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

About Botanix Pharmaceuticals

Botanix Pharmaceuticals is an Australian clinical dermatology company focused on developing and commercializing innovative treatments for common skin diseases. Their lead product candidate is Sofdra, a potential treatment for primary axillary hyperhidrosis, and they are also developing other products for acne and atopic dermatitis.

Company profile →

Botanix Pharmaceuticals (ASX:BOT) has 0.63% of its shares on issue reported as short positions as of 8 Oct 2026, or about 17,277,216 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has risen 0.38 percentage points. Its highest recorded short interest was 5.23% in July 2025. BOT is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Short interest

History & FAQ →

Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.

Strategy fit

How each stock picker strategy reads BOT today

Zanger BreakoutWatchScore 25rank 924 of 1942
CAN SLIMWatchScore 10rank 1027 of 1541
Minervini Trend TemplateNot a candidate
Crowded-Short BreakoutNot a candidate
Quality compoundersWatchScore 25rank 522 of 1669

Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →

BOT fundamentals

In the year to 30 Jun 2026, Botanix Pharmaceuticals (ASX:BOT) recorded revenue of A$33.8M and a net loss after tax of A$69.8M. A year earlier it recorded revenue of A$5.8M and a net loss after tax of A$86.4M. Year-on-year growth: revenue +487.1% (FY). Net margin −206.4%, return on equity −96.4% (FY). Figures are in AUD, the company's reporting currency; source: Yahoo Finance, as at 14 Oct 2026.

Full statements, ratios and filings are on the Financials tab. Not financial advice.

Full financials →